Tang Sumin, Zhang Yuqing, Song Liying, Hui Kaiyuan, Jiang Xiaodong
Department of Thyroid and Breast Tumor Surgery.
Department of Oncology, Lianyungang Clinical College of Nanjing Medical University/The First People's Hospital of Lianyungang.
Anticancer Drugs. 2025 Mar 1;36(3):246-252. doi: 10.1097/CAD.0000000000001678. Epub 2025 Jan 6.
Triple-negative breast cancer (TNBC) is highly prone to early relapse and metastasis following standard treatment. CXCL8 is a key factor in tumor invasion and metastasis, but its role in TNBC prognosis and clinicopathological correlations remains poorly understood. This study investigated CXCL8 expression and its clinical significance in TNBC to develop a prognostic nomogram for guiding intensive treatment and follow-up strategies. Public datasets from the gene expression omnibus public datasets platform were analyzed to assess CXCL8 expression. Additionally, paraffin-embedded TNBC specimens collected from our hospital were examined using immunohistochemistry to explore the relationship between CXCL8 expression and clinicopathological features. Survival analysis was performed to evaluate whether CXCL8 serves as an unfavorable prognostic biomarker for TNBC patients. Univariate Cox regression analysis was conducted to identify prognostic factors. Based on these findings, a nomogram was developed to predict TNBC progression risk. CXCL8 expression was significantly higher in TNBC tissues than in adjacent normal tissues ( P < 0.05). Among 122 TNBC patients, 46 were CXCL8-positive and 76 were CXCL8-negative. CXCL8 expression was significantly associated with N stage ( P < 0.05). Progression-free survival (PFS) was markedly shorter in the CXCL8-positive group compared with the CXCL8-negative group ( P < 0.001). Univariate Cox regression identified N1-3, M1, and CXCL8 positivity as significant risk factors for disease progression. A nomogram incorporating these variables (N, M, and CXCL8) was constructed to predict PFS. Time-dependent receiver operating characteristic curve analysis at 12-, 36-, and 48-month demonstrated strong predictive performance, with area under the curve values of 0.857, 0.839, and 0.795, respectively. CXCL8 is highly expressed in TNBC and promotes lymphatic metastasis, serving as an unfavorable prognostic factor. The developed nomogram offers a valuable tool for guiding personalized treatment and follow-up strategies in TNBC patients.
三阴性乳腺癌（TNBC）在标准治疗后极易早期复发和转移。CXCL8是肿瘤侵袭和转移的关键因素，但其在TNBC预后及临床病理相关性方面的作用仍知之甚少。本研究调查了CXCL8在TNBC中的表达及其临床意义，以制定一个预后列线图来指导强化治疗和随访策略。分析了来自基因表达综合公共数据集平台的公共数据集，以评估CXCL8的表达。此外，采用免疫组织化学方法检测了我院收集的石蜡包埋TNBC标本，以探讨CXCL8表达与临床病理特征之间的关系。进行生存分析以评估CXCL8是否作为TNBC患者的不良预后生物标志物。进行单因素Cox回归分析以确定预后因素。基于这些发现，开发了一个列线图来预测TNBC进展风险。TNBC组织中CXCL8表达明显高于相邻正常组织（P < 0.05）。在122例TNBC患者中，46例CXCL8阳性，76例CXCL8阴性。CXCL8表达与N分期显著相关（P < 0.05）。与CXCL8阴性组相比，CXCL8阳性组的无进展生存期（PFS）明显缩短（P < 0.001）。单因素Cox回归确定N1-3、M1和CXCL8阳性是疾病进展的显著危险因素。构建了一个包含这些变量（N、M和CXCL8）的列线图来预测PFS。在12个月、36个月和48个月时进行的时间依赖性受试者工作特征曲线分析显示出强大的预测性能，曲线下面积值分别为0.857、0.839和0.795。CXCL8在TNBC中高表达并促进淋巴转移，是一个不良预后因素。所开发的列线图为指导TNBC患者的个性化治疗和随访策略提供了一个有价值的工具。
